Cargando…

Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform

BACKGROUND: Socioeconomic differences in receipt of adjuvant treatment contribute to persistent disparities in breast cancer (BCA) outcomes, including survival. Adjuvant endocrine therapy (AET) substantially reduces recurrence risk and is recommended by clinical guidelines for nearly all women with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eom, Kirsten Y., van Londen, G. J., Li, Jie, Dahman, Bassam, Bradley, Cathy, Sabik, Lindsay M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088064/ https://www.ncbi.nlm.nih.gov/pubmed/33933027 http://dx.doi.org/10.1186/s12885-021-08149-0

Ejemplares similares

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

Assessing characteristics of populations seen at Commission on Cancer facilities using Pennsylvania linked data
por: Reed, Kristine G, et al.
Publicado: (2023)

Colon Cancer Treatment Costs for Medicare and Dually Eligible Beneficiaries
por: Luo, Zhehui, et al.
Publicado: (2009)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Suboptimal geographic accessibility to comprehensive HIV care in the US: regional and urban–rural differences
por: Masiano, Steven P, et al.
Publicado: (2019)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors
por: Camacho, Fabian T., et al.
Publicado: (2017)

Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer
por: Horii, R, et al.
Publicado: (2007)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Breast density predicts endocrine treatment outcome in the adjuvant setting
por: Cuzick, Jack
Publicado: (2012)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
por: Lambert, Leah K., et al.
Publicado: (2018)

Enrollee characteristics and receipt of colorectal cancer testing in Pennsylvania after adoption of the Affordable Care Act Medicaid expansion
por: Eom, Kirsten Y., et al.
Publicado: (2023)

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010)

Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
por: Lee, Joo Yun, et al.
Publicado: (2018)

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity
por: Wulaningsih, W., et al.
Publicado: (2018)

Correction: Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Treatment Disparities in Radiation and Hormone Therapy Among Women Covered by Medicaid vs Private Insurance in Cancer Registry and Claims Data
por: Bradley, Cathy J., et al.
Publicado: (2023)

Building Data Infrastructure for Disease-Focused Health Economics Research
por: Bradley, Cathy J., et al.
Publicado: (2023)

Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer
por: Shinn, Eileen H., et al.
Publicado: (2022)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
por: Güth, U, et al.
Publicado: (2008)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
por: Makubate, B, et al.
Publicado: (2013)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Causal Attributions in Breast Cancer Patients Planning to Undergo Adjuvant Endocrine Therapy
por: Park, Seul Ki, et al.
Publicado: (2021)

Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy
por: Tan, Eng Hooi, et al.
Publicado: (2021)

Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer
por: Lambert, Leah K., et al.
Publicado: (2021)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
por: Bekes, Inga, et al.
Publicado: (2023)

The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
por: Gomaa, Sameh, et al.
Publicado: (2023)

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome
por: Schrijver, Willemijne, et al.
Publicado: (2018)

Cancer Treatment Data in Central Cancer Registries: When Are Supplemental Data Needed?
por: Bradley, Cathy J, et al.
Publicado: (2022)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia
por: Saiful Bahri, Athirah, et al.
Publicado: (2021)

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
por: Sella, Tal, et al.
Publicado: (2023)

The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy
por: Jiang, Haoran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u2ac5e06h5s17tagabf148av7n